Background: COPD is one of the commonest disorders around the world and the causes of morbidity and mortality. Acute COPD symptoms can be managed medically. For severe exacerbations, hospitalisation may be required. OPEP devices, have been shown to help in COPD exacerbation. AEROBIKA® is a portable mechanical OPEP device in which patients blow against a variable resistance that is manually adjusted. It prevents the alveoli from collapsing. Various OPEP devices can help patients with stable COPD not only clear mucus but also improve short-term lung capacity, agility, and QOL. Aerobika has been shown to enhance (FVC), (6MWD) in COPD patients. Aim: To review the accountability of effectiveness of aerobika® in patients with COPD. Method: In this scoping review articles are researched from the search engines like PUBMED. These articles are reviewed according to the inclusion criteria which include last 6 years of articles, experimental and pilot study, observational, retrospective cohort study. 10 articles were selected according to it. Result: Articles selected for the review are research studies conducted on aerobika ®, COPD, familiar comorbidities, post-surgical patients. All studies assessed for the review showed a significant positive effect on the COPD patients who used the Aerobika®. Discussion: The discussion is based on the results of all the 7 articles included in this review. Among them all the 6 articles have individually stated that aerobika® have been proven to be clinically effective in the treatment of post exacerbation COPD patients. Aerobika® in comparison to other OPEP devices have lower rates of severe disease exacerbation in COPD patients.